← Oncology Approval Tracker

FDA DECISION ·

Tukysa + trastuzumab

tucatinib + trastuzumab · Seagen

Accelerated approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with unresectable or metastatic RAS wild-type, HER2-positive colorectal cancer after progression on fluoropyrimidine, oxaliplatin and irinotecan-based therapy.

LAMPGEN ANALYSIS

Why it matters

The accelerated approval introduced a HER2-directed combination for a selected colorectal cancer subgroup.

What research teams should watch

Confirm both RAS and HER2 status, verify prior chemotherapy, and track confirmatory evidence.

PRIMARY RECORDS

Sources